Puma Biotechnology Inc (PBYI NASDAQ) stock market data APIs
$5.1909
-0.09(-1.7%)
as of October 24, 2025
Try our APIs with
free plan!
Puma Biotechnology Inc Financial Data Overview
Price chart is built with
Anychart
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Prev. Close
5.1909
Open
5.0969
High
5.2388
Low
5.0969
52 wk Range
2.32-6.07
Market Cap
263 M
P/E Ratio
5.0777
Shares Outstanding
50 371 K
Revenue
238 M
EPS
0
Beta
1.384
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Puma Biotechnology Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Puma Biotechnology Inc data using free add-ons & libraries
Get Puma Biotechnology Inc Fundamental Data
Puma Biotechnology Inc Fundamental data includes:
- Net Revenue: 238 M
- EBITDA: 57 342 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: 0.155
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Puma Biotechnology Inc News
New
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
LOS ANGELES, October 23, 2025--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, Nov. 6, 2025...
CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains?
CRISPR Therapeutics AG CRSP shares soared 8.7% in the last trading session to close at $76.78. The move was backed by solid volume with far more shares changing hands than in a normal session. This co...
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES, October 02, 2025--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 1, 2025, the Compensation Committee of Puma’s Board of...
September 2025's Promising Penny Stocks Revealed
As U.S. markets navigate a rebound with the Nasdaq and S&P 500 rising, investors are keeping a close eye on potential government shutdowns and economic shifts. Amid these broader market movements, pen...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
